Open Access Open Access  Restricted Access Subscription Access

Analytical Method Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Mefenamic acid and Tizanidine HCl

Ashutosh Agarwal, Zeal Naik, Ragini Sharma, Nikita Patel, Parixit Prajapati

Abstract


High performance liquid chromatography (HPLC) method has been developed and validated for the estimation of Mefenamic acid and Tizanidine tablets. A simple, rapid, accurate and precise HPLC method was developed for quantification of Mefenamic acid and Tizanidine HCl. The developed method used the mixture of Acetonitrile and Water (90:10, v/v) as mobile phase at a flow rate of 1.0 mL/min, Detection was carried out at 250 nm. The linearity for Mefenamic acid of the proposed method was found in the concentration range of 125-625 ppm with regression coefficient (R2) of 0.998 and the linearity for Tizanidine of the proposed method was found in the concentration range of 0.75-2.5 ppm with regression coefficient (R2) of 0.999. LOD and LOQ for Mefenamic acid were found to be 0.1847µg/ml and 0.5598µg/ml and LOD and LOQ for Tizanidine were found to be 0.0151µg/ml and 0.0458 µg/ml, respectively. The % recovery of the suggested technique for Mefenamic acid was set up to be 99.2 %-99.7% and for Tizanidine was found to be 99.5 %-100.3%. The method was found to be precise and robust. The developed HPLC method was successfully applied for quantification of Mefenamic acid and Tizanidine in marketed tablet.

 


Full Text:

PDF

References


Solanki R, Nagori BP, Naval MK, Banerjee J. Development and validation of simultaneous estimation method for amoxycillin trihydrate and tinidazole in tablet dosage form by rp-hplc. Asian Journal of Pharmaceutical Analysis. 2013;3(2):66-71.

Laxman MP, Thange MT. A Review on High Performance Liquid Chromatography. International Journal of Research Publication and Reviews, Vol 3, no 7, pp 3014-3028, July 2022.

Balali-Mood M, Proudfoot AT, Critchley JA, Prescott LF. Mefenamic acid overdosage. The Lancet.Vol:317(8234): pp1354-6; 1981 Jun.

Cimolai N. The potential and promise of mefenamic acid. Expert review of clinical pharmacology.Vol 6(3):pp289-305, 2013 May.

Adam A, Schrimpl L, Schmidt PC. Some physicochemical properties of mefenamic acid. Drug development and industrial pharmacy, Vol 26(5), pp477-87, 2000 Jan.

Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Bmj.Vol 313(7057), pp:579-82, 1996 Sep.

Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin, Vol 24(2), Cimolai N. The potential and promise

of mefenamic acid. Expert review of clinical pharmacology. 2013 May 1;6(3):289-305. pp425-39,2008 Feb.

Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. British journal of clinical pharmacology, Vol 57(3), pp 349-353, 2004 Mar.

Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opinion on Pharmacotherapy.vol9(12); pp2209-15:2008 Aug 1.

Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology.Vol44(11 Suppl 9): ppS6-10:1994 Nov.


Refbacks

  • There are currently no refbacks.